<DOC>
	<DOCNO>NCT00042393</DOCNO>
	<brief_summary>The purpose early access protocol provide access adefovir dipivoxil prior commercial availability people lamivudine-resistant chronic hepatitis B limit treatment option .</brief_summary>
	<brief_title>An Open-Label Program Adefovir Dipivoxil Treatment Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options</brief_title>
	<detailed_description>Due considerable unmet medical need patient chronic hepatitis B , Gilead initiate early access program make investigational drug , adefovir dipivoxil 10 mg , available patient lamivudine-resistant chronic hepatitis B risk disease progression . Protocol GS-01-550 provide access patient lamivudine-resistant hepatitis B virus need alternative treatment suppress HBV DNA replication prevent progressive liver disease .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . =/ &gt; 16 year age ( minimum age require give country ) . 2 . Prior lamivudine therapy cumulative period &gt; 24 week genotypic evidence lamivudine resistance . 3 . Clinical evidence lamivudineresistant hepatitis B define positive serum hepatitis B virus ( HBV ) DNA great equal 10^6 copies/mL ( PCR assay ) ALT great equal 1.2 X upper limit normal ( ULN ) within 4 week screen despite ongoing therapy lamivudine . 4 . Treating physician feel patient risk disease progression . 5 . Screening laboratory value measure follow , within 28 day prior baseline visit : Adequate hematologic function . Absolute neutrophil count =/ &gt; 750/mm3 , platelet =/ &gt; 50,000/mm3 , hemoglobin =/ &gt; 7.5 g/dL . 6 . Females childbearing potential must negative serum urine pregnancy test screening period . Females must use effective method ( ) contraception heterosexual intercourse adefovir dipivoxil least 30 day follow treatment discontinuation . 7 . Able understand sign inform consent prior undergo study procedure able comply requirement study . 8 . Patients coinfected HIV , hepatitis C virus ( HCV ) , viral infection eligible participate provide meet entry criterion . Patients meet entry criterion treat physician believe chronic hepatitis B disease progression premature death likely occur absence early access adefovir dipivoxil consider casebycase basis Parexel medical monitor . 1 . Patients serious active medical psychiatric illness , opinion investigator , would interfere patient treatment , assessment , compliance protocol dosing requirement . 2 . Patients hypersensitivity component drug product . 3 . Currently receive nephrotoxic drug ( exception cyclosporine tacrolimus patient post liver transplantation ) aminoglycosides ( e.g. , amikacin , gentamicin , kanamycin , neomycin , netilmicin , streptomycin , tobramycin ) , conventional amphotericin B , intravenous ( IV ) vancomycin , cidofovir , IV foscarnet , cisplatin , IV pentamidine OR competitor renal excretion probenecid sulfinpyrazone . These agent must discontinue least 7 day prior start treatment adefovir dipivoxil . 4 . Currently enrol another clinical trial adefovir dipivoxil . 5 . HIV HBV coinfected patient receive tenofovir disoproxil fumarate [ Viread ( R ) ] HIV disease . 6 . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatitis B , Chronic</keyword>
</DOC>